Since chemotherapy for metastatic breast cancer is not curative, consideration of the quality of life is important in selecting a treatment regimen. We conducted a randomized trial comparing continuous chemotherapy, administered until disease progression was evident, with intermittent therapy, whereby treatment was stopped after three cycles and then repeated for three more cycles only when there was evidence of disease progression. Each approach was tested with doxorubicin combined with cyclophosphamide or with cyclophosphamide combined with methotrexate, fluorouracil, and prednisone. Intermittent therapy resulted in a significantly worse response (P = 0.02 by Mann-Whitney test), a significantly shorter time to disease progression (relative risk based on proportional-hazards model, 1.8; 95 percent confidence interval, 1.4 to 2.4), and a trend toward shorter survival (relative risk, 1.3; confidence interval, 0.99 to 1.6). The quality of life was expressed as linear-analogue self-assessment scores for physical well-being, mood, pain, and appetite and as a quality-of-life index. It improved significantly during the first three cycles, when all patients received treatment. Thereafter, intermittent therapy was associated with worse scores for physical well-being (by 23 percent of scale; 95 percent confidence interval, 11 to 35 percent), mood (25 percent; 13 to 37 percent), and appetite (12 percent; 0 to 24 percent) and for the quality-of-life index as indicated by the patient (14 percent; 5 to 23 percent) and the physician (16 percent; 7 to 26 percent). Changes in the quality of life were independent prognostic factors in proportional-hazards models of subsequent survival. We conclude that, as tested, continuous chemotherapy is better than intermittent chemotherapy for advanced breast cancer.
Source Information
Ludwig Institute for Cancer Research (Sydney Branch), University of Sydney, N.S.W., Australia.
This article has been cited by other articles:
Ganz, P. A., Gotay, C. C.
(2007). Use of Patient-Reported Outcomes in Phase III Cancer Treatment Trials: Lessons Learned and Future Directions. JCO
25: 5063-5069
[Abstract][Full Text]
Colozza, M., de Azambuja, E., Personeni, N., Lebrun, F., Piccart, M. J., Cardoso, F.
(2007). Achievements in Systemic Therapies in the Pregenomic Era in Metastatic Breast Cancer. The Oncologist
12: 253-270
[Abstract][Full Text]
Gennari, A., Amadori, D., De Lena, M., Nanni, O., Bruzzi, P., Lorusso, V., Manzione, L., Conte, P. F.
(2006). Lack of Benefit of Maintenance Paclitaxel in First-Line Chemotherapy in Metastatic Breast Cancer. JCO
24: 3912-3918
[Abstract][Full Text]
Rothschild, B. B., King, N. M.P., Muggia, F. M., Sekine, I., Tamura, T., Miller, M. J., Horstmann, E., Emanuel, E. J., Grady, C., Kurzrock, R., Benjamin, R. S.
(2005). Phase 1 Clinical Trials in Oncology. NEJM
352: 2451-2453
[Full Text]
Toscani, F., Brunelli, C., Miccinesi, G., Costantini, M., Gallucci, M., Tamburini, M., Paci, E., Di Giulio, P., Peruselli, C.
(2005). Predicting survival in terminal cancer patients: clinical observation or quality-of-life evaluation?. Palliat Med
19: 220-227
[Abstract]
Hainsworth, J. D., Litchy, S., Shaffer, D. W., Lackey, V. L., Grimaldi, M., Greco, F. A.
(2005). Maximizing Therapeutic Benefit of Rituximab: Maintenance Therapy Versus Re-Treatment at Progression in Patients With Indolent Non-Hodgkin's Lymphoma--A Randomized Phase II Trial of the Minnie Pearl Cancer Research Network. JCO
23: 1088-1095
[Abstract][Full Text]
Sparano, J. A., Bernardo, P., Stephenson, P., Gradishar, W. J., Ingle, J. N., Zucker, S., Davidson, N. E.
(2004). Randomized Phase III Trial of Marimastat Versus Placebo in Patients With Metastatic Breast Cancer Who Have Responding or Stable Disease After First-Line Chemotherapy: Eastern Cooperative Oncology Group Trial E2196. JCO
22: 4683-4690
[Abstract][Full Text]
Dagher, R., Johnson, J., Williams, G., Keegan, P., Pazdur, R.
(2004). Accelerated Approval of Oncology Products: A Decade of Experience. JNCI J Natl Cancer Inst
96: 1500-1509
[Abstract][Full Text]
Lal, R., Dickson, J., Cunningham, D., Chau, I., Norman, A. R., Ross, P. J., Topham, C., Middleton, G., Hill, M., Oates, J.
(2004). A Randomized Trial Comparing Defined-Duration With Continuous Irinotecan Until Disease Progression in Fluoropyrimidine and Thymidylate Synthase Inhibitor--Resistant Advanced Colorectal Cancer. JCO
22: 3023-3031
[Abstract][Full Text]
Yano, S., Zhang, H., Hanibuchi, M., Miki, T., Goto, H., Uehara, H., Sone, S.
(2003). Combined Therapy with a New Bisphosphonate, Minodronate (YM529), and Chemotherapy for Multiple Organ Metastases of Small Cell Lung Cancer Cells in Severe Combined Immunodeficient Mice. Clin. Cancer Res.
9: 5380-5385
[Abstract][Full Text]
Ozols, R. F.
(2003). Maintenance Therapy in Advanced Ovarian Cancer: Progression-Free Survival and Clinical Benefit. JCO
21: 2451-2453
[Full Text]
Goodwin, P. J., Black, J. T., Bordeleau, L. J., Ganz, P. A.
(2003). Health-Related Quality-of-Life Measurement in Randomized Clinical Trials in Breast Cancer--Taking Stock. JNCI J Natl Cancer Inst
95: 263-281
[Abstract][Full Text]
Bottomley, A.
(2002). The Cancer Patient and Quality of Life. The Oncologist
7: 120-125
[Abstract][Full Text]
Cardoso, F., Di Leo, A., Lohrisch, C., Bernard, C., Ferreira, F., Piccart, M. J.
(2002). Second and subsequent lines of chemotherapy for metastatic breast cancer: what did we learn in the last two decades?. Ann Oncol
13: 197-207
[Abstract][Full Text]
Bernhard, J., Maibach, R., Thurlimann, B., Sessa, C., Aapro, M. S.
(2002). Patients' Estimation of Overall Treatment Burden: Why Not Ask the Obvious?. JCO
20: 65-72
[Abstract][Full Text]
McLachlan, S.-A., Allenby, A., Matthews, J., Wirth, A., Kissane, D., Bishop, M., Beresford, J., Zalcberg, J.
(2001). Randomized Trial of Coordinated Psychosocial Interventions Based on Patient Self-Assessments Versus Standard Care to Improve the Psychosocial Functioning of Patients With Cancer. JCO
19: 4117-4125
[Abstract][Full Text]
Del Mastro, L., Venturini, M., Lionetto, R., Carnino, F., Guarneri, D., Gallo, L., Contu, A., Pronzato, P., Vesentini, L., Bergaglio, M., Comis, S., Rosso, R.
(2001). Accelerated-Intensified Cyclophosphamide, Epirubicin, and Fluorouracil (CEF) Compared With Standard CEF in Metastatic Breast Cancer Patients: Results of a Multicenter, Randomized Phase III Study of the Italian Gruppo Oncologico Nord-Ouest-Mammella Inter Gruppo Group. JCO
19: 2213-2221
[Abstract][Full Text]
Smith, I. E., O'Brien, M. E.R., Talbot, D. C., Nicolson, M. C., Mansi, J. L., Hickish, T. F., Norton, A., Ashley, S.
(2001). Duration of Chemotherapy in Advanced Non-Small-Cell Lung Cancer: A Randomized Trial of Three Versus Six Courses of Mitomycin, Vinblastine, and Cisplatin. JCO
19: 1336-1343
[Abstract][Full Text]
Coates, A. S., Hurny, C., Peterson, H. F., Bernhard, J., Castiglione-Gertsch, M., Gelber, R. D., Goldhirsch, A.
(2000). Quality-of-Life Scores Predict Outcome in Metastatic but Not Early Breast Cancer. JCO
18: 3768-3774
[Abstract][Full Text]
(2000). Epirubicin-Based Chemotherapy in Metastatic Breast Cancer Patients: Role of Dose-Intensity and Duration of Treatment. JCO
18: 3115-3124
[Abstract][Full Text]
Morreim, E. H.
(2000). Quality of Life: Erosions and Opportunities Under Managed Care. J Law Med Ethics
28: 144-158
Vigano, A., Bruera, E., Jhangri, G. S., Newman, S. C., Fields, A. L., Suarez-Almazor, M. E.
(2000). Clinical Survival Predictors in Patients With Advanced Cancer. Arch Intern Med
160: 861-868
[Abstract][Full Text]
Cheng, J. D., Hitt, J., Koczwara, B., Schulman, K. A., Burnett, C. B., Gaskin, D. J., Rowland, J. H., Meropol, N. J.
(2000). Impact of Quality of Life on Patient Expectations Regarding Phase I Clinical Trials. JCO
18: 421-421
[Abstract][Full Text]
Chan, S., Friedrichs, K., Noel, D., Pinter, T., Van Belle, S., Vorobiof, D., Duarte, R., Gil Gil, M., Bodrogi, I., Murray, E., Yelle, L., von Minckwitz, G., Korec, S., Simmonds, P., Buzzi, F., Gonzalez Mancha, R., Richardson, G., Walpole, E., Ronzoni, M., Murawsky, M., Alakl, M., Riva, A., Crown, J.
(1999). Prospective Randomized Trial of Docetaxel Versus Doxorubicin in Patients With Metastatic Breast Cancer. JCO
17: 2341-2341
[Abstract][Full Text]
Bishop, J. F., Dewar, J., Toner, G. C., Smith, J., Tattersall, M. H.N., Olver, I. N., Ackland, S., Kennedy, I., Goldstein, D., Gurney, H., Walpole, E., Levi, J., Stephenson, J., Canetta, R.
(1999). Initial Paclitaxel Improves Outcome Compared With CMFP Combination Chemotherapy as Front-Line Therapy in Untreated Metastatic Breast Cancer. JCO
17: 2355-2355
[Abstract][Full Text]
Bernhard, J., Thurlimann, B., Schmitz, S.-F. H., Castiglione-Gertsch, M., Cavalli, F., Morant, R., Fey, M.F., Bonnefoi, H., Goldhirsch, A., Hurny, C.
(1999). Defining Clinical Benefit in Postmenopausal Patients With Breast Cancer Under Second-Line Endocrine Treatment: Does Quality of Life Matter?. JCO
17: 1672-1672
[Abstract][Full Text]
Carter, K. J., Ritchey, N. P., Castro, F., Caccamo, L. P., Kessler, E., Erickson, B. A.
(1999). Analysis of Three Decision-making Methods: A Breast Cancer Patient as a Model. Med Decis Making
19: 49-57
[Abstract]
Martin, A. J., Stockler, M.
(1998). Quality-of-Life Assessment in Health Care Research and Practice. Eval Health Prof
21: 141-156
[Abstract]
Ellison, N. M.
(1998). Palliative chemotherapy. AM J HOSP PALLIAT CARE
15: 93-103
Kao, G., Rubiales, A. S., Centeno, C., Hortobagyi, G. N., Theriault, R. L., Seaman, J.
(1997). Pamidronate and Metastatic Breast Cancer. NEJM
336: 1609-1610
[Full Text]
Richards, M., Ramirez, A.
(1997). Quality of life: the main outcome measure of palliative care. Palliat Med
11: 89-92
Bennett, M. I., Alison, D. L., O'Neill, W. M., Mclllmurray, M.
(1996). Questions of training- choice or force?. Palliat Med
10: 43-47
[Abstract]
Koopmans, P P
(1995). Registration of drugs for treating cancer and HIV infection: a plea to carry out phase 3 trials before admission to the market. BMJ
310: 1305-1306
[Full Text]
Allsopp, M.A., Sewell, G.J.
(1995). A pharmacokinetic-pharmacodynamic study on carboplatin administered in prolonged continuous infusion regimens with synchronous radiotherapy. J Oncol Pharm Pract
1: 25-32
[Abstract]
Kearsley, J. H
(1994). Some basic guidelines in the use of chemotherapy for patients with incurable malignancy. Palliat Med
8: 11-17
[Abstract]
(1987). QUALITY OF LIFE WITH CONTINUOUS VERSUS INTERMITTENT CHEMOTHERAPY. JWatch General
1987: 4-4
[Full Text]
Previous
